Company Profile

Genalyte Inc
Profile last edited on: 4/14/2021      CAGE: 5CS08      UEI: LJWNUEZ6U8A9

Business Identifier: Empowering physician-patient interaction: real-time diagnostics and healthcare analytics
Year Founded
2007
First Award
2011
Latest Award
2013
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

10520 Wateridge Circle
San Diego, CA 92121
   (858) 956-1200
   sales@genalyte.com
   www.genalyte.com
Location: Single
Congr. District: 52
County: San Diego

Public Profile

With facilities in San Diego CA and Austin TX, Genalyte delivers rapid, actionable results to doctors through decentralized laboratory testing. The firm in the business of developing instrument systems - hardware, software and consumables - to make multiplex protein and nucleic acid testing from a single sample the standard in the research, life science and clinical diagnostic markets. Genalyte's multiplexing platform incorporates the company's Microring Sensor Technology™, a new approach to multiplexing that reduces or eliminates sample preparation, provides scalable multiplexing for both proteins and nucleic acids from a single small sample, and achieves up to eight logs of dynamic range. Tthe Maverick™ platform being launched by the firm uses this technology to run scalable multiplexed assays that do not require the washes, incubations or other processing steps associated with sample preparation. The firm's Maverick™ platform has a large dynamic range and excellent sensitivity. Maverick Detection System that uses a silicon chip containing arrays of photonic ring sensors that simultaneously analyze multiple antibodies and other proteins from a single small sample; and autoantibody testing assays for autoimmune research. It provides custom spotting services; Maverick microring photonics multiplex assay system that delivers results from small samples of various types, including serum, plasma, culture media, and whole blood; and Genalyte T1D antigen panel, a multiplexed assay that measures autoantibodies associated with the destruction of pancreatic islet cells seen in type 1 diabetes. The firm is commercializing the MaverickTM Detection System based on the company’s revolutionary Microring Sensor Technology™, a new approach to multiplexing that uses a silicon chip containing arrays of photonic ring sensors to reduce or eliminate sample preparation and provide scalable multiplexing for both proteins and nucleic acids. The one-step workflow of the Maverick System can deliver accurate results in as little as 15 minutes from small volume samples of many types. It has a large dynamic range and excellent sensitivity with outstanding reproducibility.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
50-74
Revenue Range
5M-7.5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
25-49

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2013 2 NIH $523,479
Project Title: T1d Multiplex Assay to Profile Predisposition and Progression of Autoimmune Statu
2011 1 NIH $199,945
Project Title: Rapid Multiplexed Detection Of Cancer Related Proteins

Key People / Management

  Cary Gunn -- President, CEO and Founder

  Kevin Lo -- President

  Alex Batchelor -- Head of Sales and Marketing

  Rufus Burlingame -- Vice President of Diagnostic Assay Development

  Richard Ellson

  Hossein Fakhrai-Rad

  Martin Gleeson -- Chief Scientific Officer,

  Richard D Hockett -- Chief Medical Officer

  Christopher Johnson -- Director of Engineering

  Prakash Menon -- CTO, BaseHealth Analytics at Genalyte. Additionally, Prakas

  Ian Wisenberg -- Chief Financial Officer